FindTrial
Sign In

The Study on the Mechanism of Osimertinib-induced Pulmonary Toxicity through Up-regulating TRAPPC9 in Lung Epithelial Cells to Activate Secretory Autophagy and Recruit Macrophages

The Study on the Mechanism of Osimertinib-induced Pulmonary Toxicity through Up-regulating TRAPPC9 in Lung Epithelial Cells to Activate Secretory Autophagy and Recruit Macrophages

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115251
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-12-25
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic tumor/non-small cell lung cancer

Interventions

Case Group:None
Control group:None

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: A study was conducted using 50 lung cancer patients treated with osimertinib (if the number of surgical patients after osimertinib administration was less than 50, 100 surgical patients who did not receive osimertinib were used to make up for the total), including detailed information such as past medical history and osimertinib medication records, along with corresponding cancerous and adjacent tissues, with samples sourced from the pathology department. Meanwhile, cancer and adjacent tissue samples from 50 lung cancer patients with matched tumor stages but who did not receive osimertinib treatment were selected as the control group.

Exclusion criteria

Exclusion criteria: Patients with other unexplained lung injury.

Design outcomes

Primary

MeasureTime frame
Immunohistochemical staining results;—

Countries

China

Contacts

Public ContactYueping Qiu

Zhejiang Cancer Hospital

qiuyp@zjcc.org.cn+86 571 8812 2438

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026